市場調查報告書

鈣拮抗劑的全球市場:成長,趨勢,預測(2020年∼2025年)

Calcium Channel Blocker Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 927874
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
價格
鈣拮抗劑的全球市場:成長,趨勢,預測(2020年∼2025年) Calcium Channel Blocker Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 117 Pages
簡介

心血管疾病的流行和人們生活方式的改變有望促進鈣拮抗劑市場的增長。高血壓是心臟病的主要原因之一。根據世界衛生組織的數據,全世界約有11.3億人患有高血壓。此外,心血管疾病是主要的死亡原因之一,2016年導致約1790萬人死亡。已知鈣拮抗劑在該適應症中是有效的,並且對該市場的需求正在穩定增長。但是,近年來,也發現了一些產品召回的情況,這可能會限制市場的增長。

本報告提供全球鈣拮抗劑市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各市場區隔和各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 心血管疾病增加的負擔
    • 人們的生活方式的變化
  • 阻礙市場要素
    • 產品的回收
  • 波特的五力分析

第5章 市場區隔

  • 各藥物類別
    • 二氫吡啶
    • 苯佐替平
    • 苯烷基胺
  • 各流通管道
    • 醫院
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbvie Inc
    • Alvogen
    • Arbor Pharmaceuticals LLC
    • Bausch Health Company Inc.
    • Covis Pharma BV
    • Exela Pharma Sciences, LLC
    • GlaxoSmithKline LLC
    • Novartis AG
    • Pfizer Inc
    • Silvergate Pharmaceuticals Inc.

第7章 市場機會及未來趨勢

目錄
Product Code: 68200

The Calcium Channel Blocker Market is expected to register a CAGR of 5.1 % during the forecast period. The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred as the elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of the death and around 17.9 million people died in 2016 due to it. Calcium antagonist are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of the cardiovascular diseases. However, the recent years, also observed some cases related to product recalls which restricts the growth of the studied market.

Key Market Trends

Dihydropyridines Segment is Expected to Hold a Major Share in the Calcium Channel Blocker Market

  • Though the mechanism of action is similar in all the classes, the pharmacological effects vary. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes.
  • Also, dihydropyridine calcium channel blockers are majorly prescribed over others in most of the Asia-Pacific region, as reported by the study of Journal of Clinical Hypertension, 2016.
  • Moreover, the fourth generation dihydropyridine drug, cilnidipine is considered as an effective treatment against autonomic dysfunction which is a key risk factor for atrial fibrillation. It inhibits L-type calcium as well as N-type of calcium, and are able to dilate efferent and afferent arteriole effectively. Hence, these factors are expected to propel the dihydropyridine segment of calcium Channel blocker market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyle among people and increasing prevalence rate of cardiovascular diseases. The adoption of sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% - 85% of people, worldwide, have adopted a sedentary life. According to Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in U.S., at least one person dies every 37 second due to cardiovascular disease, as reported by Centre for Disease Control and Prevention.

Competitive Landscape

The Calcium Channel Blocker Market is fragmented and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc, Alvogen, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cardiovascular Diseases
    • 4.2.2 Changing Lifestyle of People
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Dihydropyridine
    • 5.1.2 Benzothizepine
    • 5.1.3 Phenylalkylamine
  • 5.2 By Distribution Channel
    • 5.2.1 Hospitals
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc
    • 6.1.2 Alvogen
    • 6.1.3 Arbor Pharmaceuticals LLC
    • 6.1.4 Bausch Health Company Inc.
    • 6.1.5 Covis Pharma BV
    • 6.1.6 Exela Pharma Sciences, LLC
    • 6.1.7 GlaxoSmithKline LLC
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc
    • 6.1.10 Silvergate Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS